secwatch.observer — SEC 8-K summary
======================================

Issuer:     JOHNSON & JOHNSON (JNJ)
CIK:        0000200406
Form:       8-K
Filed at:   2026-10-13T12:12:35+00:00
Accession:  0000200406-26-000189
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

J&J Q3 sales $25.4B, up 5.9%; GAAP EPS $0.09 (-95.8%) on $5.78B other expense; adj EPS $2.59 (-7.5%)
--------------------------------------------------------------------------------

- Q3 worldwide sales $25,399M vs $23,993M, +5.9% (operations +6.0%); U.S. +9.1% to $14,959M, international +1.5% to $10,440M.
- Innovative Medicine sales $16,757M, +7.7%; MedTech $8,642M, +2.5%, with MedTech international up just 0.1%.
- GAAP net earnings fell 95.9% to $210M and diluted EPS 95.8% to $0.09, driven by $5,780M of other (income) expense, net vs $(478)M income a year ago.
- Adjusted net earnings $6,339M (-6.8%) and adjusted diluted EPS $2.59 vs $2.80 (-7.5%); adjusted effective tax rate 17.4% vs 19.4%.
- R&D expense rose 26.7% to $4,652M and IPR&D impairments were $339M; nine-month worldwide sales $74,771M, +7.4%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/200406/000020040626000189/0000200406-26-000189-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/200406/000020040626000189/jnj-20261013.htm
  HTML page:      https://secwatch.observer/filing/0000200406-26-000189

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer